Slingshot members are tracking this event:

Breakthrough Therapy Designation from U.S. FDA for LOXO-292 for the Treatment of RET Fusion-Positive Thyroid Cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 15, 2018
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Loxo-292, Thyroid Cancer